Purolite and Repligen have extended their existing ligand partnership through 2032.
Purolite, an Ecolab company and manufacturer of synthetic and agarose-based resins, announced that it had expanded and extended its ligand supply agreement with Repligen, a life sciences company who owns two facilities that produce the majority Protein A ligands, on Nov. 1, 2022.
The deal, which now runs through 2032, will see the Repligen supply Purolite with five high-performance ligands. According to a company press release, this agreement is designed for Purolite’s increased expansion in the affinity space, allowing them to provide more solutions for purification of monoclonal antibodies (mAbs) and mAb fragments currently unmet by the market.
Purolite’s jetting technology uses a patented manufacturing method that produces agarose resins that are used in the purification of therapeutics like mAbs. The technology is designed to provide precise control over bead size and distribution, allowing for significant lot-to-lot consistency, unique productivity benefits, and improved quality. According to the release, it also significantly reduces lead times and is a greener alternative to traditional manufacturing methods.
The existing partnership has led to the development and commercialization of Praesto Jetted A50 HipH, which combines Purolite’s base beads and Repligen’s ligand technology to provide a novel protein A affinity resin. According to the release, this resin is capable of eluting at milder conditions when compared to conventional protein A resins available on the market.
“We are delighted that Repligen has chosen to extend and further strengthen its agreement with Purolite to continue to commercialize their affinity ligands which are specifically designed to target antibodies and fragments combined with our innovative Praesto agarose jetting base bead technology,” said Hayley Crowe, senior vice-president and general manager, Purolite, in the release. “We look forward to continuing a productive relationship with Repligen and adding this ligand technology to our suite of products.”
Source: Purolite
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.